# TGFBR2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The TGFBR2 gene encodes a constitutively active serine/threonine kinase receptor, the primary initiator of the TGF-β signaling cascade, crucial for embryonic development, tissue homeostasis, and immune regulation.
- Germline mutations in TGFBR2 are causally linked to severe connective tissue disorders, including Loeys-Dietz syndrome and familial thoracic aortic aneurysms and dissections, often presenting with arterial tortuosity and aggressive aneurysms.
- Somatic frameshift mutations in the polyadenine tract of TGFBR2 exon 3 are a hallmark of microsatellite unstable colorectal and gastric cancers, leading to loss of TGF-β-mediated growth inhibition and apoptosis.
- TGFBR2 signaling activates canonical SMAD pathways and non-canonical pathways like MAPK/ERK and PI3K/AKT, influencing cell cycle, apoptosis, epithelial-to-mesenchymal transition (EMT), and extracellular matrix production.
- Therapeutic strategies targeting TGFBR2 include small-molecule kinase inhibitors (e.g., LY2157299), monoclonal antibodies (e.g., Fresolimumab), and antisense oligonucleotides (ASOs) for cancer and fibrotic diseases.
- TGFBR2 expression is tightly regulated by transcription factors (e.g., Sp1, NF-κB), epigenetic modifiers (e.g., EZH2), and non-coding RNAs (miRNAs and lncRNAs), with dysregulation contributing to diverse pathologies.

---

## Executive Summary & Key Metadata

The **TGFBR2** gene encodes the Transforming Growth Factor Beta Receptor 2, a constitutively active serine/threonine kinase that serves as the primary ligand-binding and initiating receptor for the TGF-β signaling cascade. This receptor is fundamental to embryonic development, adult tissue homeostasis, immune regulation, and tumor suppression. Germline mutations in TGFBR2 are causally linked to a spectrum of connective tissue disorders, most notably Loeys-Dietz syndrome (LDS) and familial thoracic aortic aneurysms and dissections (TAAD), while somatic mutations—particularly frameshift mutations in microsatellite unstable tumors—drive colorectal and gastric carcinogenesis. The receptor's dual role as both a tumor suppressor and, in later stages of malignancy, a promoter of metastasis via epithelial-to-mesenchymal transition (EMT), makes it a high-priority target for therapeutic intervention.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | TGFBR2 |
| **UniProt Accession** | P37173 |
| **Representative PDB ID** | 1PLO (extracellular domain), 5E8V (kinase domain) |
| **Chromosomal Locus** | 3p24.1 (human) |
| **Primary Molecular Function** | Serine/threonine kinase receptor; TGF-β signal transduction |
| **Disease & Pathology Associations** | Loeys-Dietz syndrome, Marfan syndrome type II, TAAD, colorectal cancer (MSI), gastric cancer, breast cancer, non-small cell lung cancer, Kawasaki disease, congenital heart defects, hypospadias, ossification of the posterior longitudinal ligament, schizophrenia, metabolic syndrome |

The gene was first mapped to human chromosome band 3p22 by Mathew et al. in 1994 using fluorescence in situ hybridization and somatic cell hybrid analysis [1]. This chromosomal region is notable for frequent loss of heterozygosity in various solid tumors, implicating TGFBR2 as a candidate tumor suppressor gene early in its characterization.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Genomic Architecture

The human TGFBR2 gene is located on the short arm of chromosome 3 at cytogenetic band **3p24.1** (GRCh38/hg38 coordinates: chr3:30,606,478-30,694,142, minus strand). The gene spans approximately 87.7 kilobases of genomic DNA and contains **7 coding exons** (exons 2-7) preceded by a large 5' untranslated region. The genomic organization is highly conserved across vertebrates; the chicken TGFBR2 (cTGFBR2) gene, for instance, exhibits a similar exon-intron structure with an intragenic tandem duplication in the 5' region that generates alternative transcript isoforms [2].

The promoter region of TGFBR2 lacks a canonical TATA box but contains multiple GC-rich elements and binding sites for the transcription factor Sp1. Additional regulatory elements include a **super-enhancer** located approximately 40 kb upstream of the transcription start site that controls TGFBR2 expression in pancreatic cancer cells; deletion of this super-enhancer via CRISPR/Cas9 results in significant downregulation of TGFBR2 mRNA and protein [1]. The promoter also contains functional binding sites for **NF-κB**, which has been shown to mediate TGFBR2 transcriptional upregulation in the context of Kawasaki disease pathogenesis [2].

### 1.2 Transcriptional Regulation and Epigenetic Control

TGFBR2 transcription is regulated by a complex interplay of transcription factors, chromatin modifiers, and non-coding RNAs. The chromatin remodeler **Pontin** (RUVBL1) recruits the transcription factor **LEF1** to the TGFBR2 promoter, where they synergistically activate transcription. This Pontin/LEF1 complex amplifies TGFBR2 expression and activates TGF-β/SMAD signaling during gliomagenesis, demonstrating that epigenetic regulation of TGFBR2 is context-dependent and can be co-opted for oncogenic purposes [1].

In non-small cell lung cancer (NSCLC), the transcriptional co-activators **YAP and TAZ** synergize with the histone methyltransferase **EZH2** to repress TGFBR2 expression. This repression occurs through the deposition of H3K27me3 marks at the TGFBR2 promoter, effectively silencing the tumor suppressor activity of the TGF-β pathway [2]. The reciprocal regulation of TGFBR2 by oncogenic and tumor suppressive transcriptional complexes highlights its central position in cellular fate decisions.

### 1.3 Alternative Splicing and Isoforms

Alternative splicing of TGFBR2 generates multiple transcript variants. The predominant full-length isoform encodes a 567-amino acid protein. A shorter isoform, generated by alternative splicing that skips exon 4, produces a truncated receptor lacking part of the extracellular domain; this isoform is unable to bind TGF-β ligand and may function as a dominant-negative regulator.

In the chicken model, 5' and 3' RACE analysis identified multiple cTGFBR2 transcript isoforms resulting from alternative promoter usage and intragenic tandem duplication events [2]. These isoforms exhibit tissue-specific expression patterns, with differential expression observed in liver, spleen, and immune tissues. The existence of multiple isoforms with potentially distinct functions underscores the regulatory complexity of TGF-β signaling.

### 1.4 Non-Coding RNA Regulation

TGFBR2 expression is extensively regulated by microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). A comprehensive list of validated regulators includes:

- **miR-20a-5p**: Targets TGFBR2 3'UTR and regulates inflammatory responses in chicken macrophages infected with avian pathogenic E. coli [1]
- **miR-204-5p**: Forms a ceRNA network with LINC00536 to regulate TGFBR2 in breast cancer [2]
- **miR-370-3p**: Mediates circARID1A effects on glioblastoma invasion via TGFBR2 [1]
- **miR-1224-5p**: Targeted by lncRNA MIR4435-2HG in glioblastoma [2]
- **miR-7**: Part of the CDR1as/miR-7/TGFBR2 axis in silica-induced pulmonary fibrosis [1]
- **miR-193b-5p**: Regulated by lncRNA N29 in cardiac hypertrophy [2]
- **miR-145**: Regulates TGFBR2 expression and matrix synthesis in vascular smooth muscle cells [1]
- **miR-135b**: Promotes colorectal cancer progression by targeting TGFBR2 [2]
- **miR-655**: EMT-suppressive miRNA targeting ZEB1 and TGFBR2 [1]
- **miR-520f**: Reverses EMT by targeting ADAM9 and TGFBR2 [2]
- **miR-3191**: Promotes migration and invasion in colorectal cancer by downregulating TGFBR2 [1]
- **miR-9**: Inhibits high glucose-induced cardiac fibrosis via TGFBR2 downregulation [2]
- **miR-216a-5p**: Alleviates LPS-induced inflammation by down-regulating TGFBR2 [1]
- **miR-337**: Associated with chondrogenesis through TGFBR2 regulation [2]
- **miR-200b**: Stimulates tumor growth in TGFBR2-null colorectal cancers [1]

This extensive miRNA regulation highlights the fine-tuned control of TGFBR2 expression across diverse physiological and pathological contexts.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The TGFBR2 protein (UniProt P37173) is a single-pass transmembrane receptor of 567 amino acids with a molecular weight of approximately 65 kDa (unglycosylated). The protein is organized into three major domains:

**N-terminal Extracellular Domain (ECD; residues 1-166):**
- Contains the signal peptide (residues 1-23) that directs co-translational insertion into the endoplasmic reticulum membrane
- The mature ECD (residues 24-166) adopts a three-finger toxin fold characterized by a central β-sheet core
- Contains three disulfide bonds (C54-C93, C61-C133, C117-C130) that stabilize the fold
- Two N-linked glycosylation sites (N94 and N110) are critical for proper folding and ligand binding
- The ECD contains the high-affinity TGF-β binding site, with key residues including W60, F69, and Y83 that form the hydrophobic ligand-binding pocket

**Transmembrane Domain (residues 167-187):**
- Single α-helical transmembrane segment
- Contains a GxxxG dimerization motif that promotes receptor homodimerization
- The juxtamembrane region (residues 188-200) contains a palmitoylation site (C197) that anchors the receptor to lipid rafts

**Intracellular Serine/Threonine Kinase Domain (residues 201-567):**
- The kinase domain adopts the canonical bi-lobal protein kinase fold
- N-lobe (residues 201-310): Contains the glycine-rich P-loop (GxGxxG motif, residues 225-230) and a conserved lysine (K277) that coordinates ATP binding
- C-lobe (residues 311-567): Contains the catalytic loop (HRDLAARN, residues 380-387), the DFG motif (D444-F445-G446), and the activation segment (residues 440-470)
- The kinase domain is constitutively active; unlike TGFBR1, TGFBR2 does not require phosphorylation for basal activity
- Autophosphorylation sites include S416, S418, and S424 in the activation segment

### 2.2 Quaternary Structure and Ligand Binding

TGFBR2 functions as a **homodimer** at the cell surface. The extracellular domains of two TGFBR2 molecules form a symmetrical dimer that binds one TGF-β ligand dimer. The ligand-binding interface involves the concave surface of the three-finger toxin fold, with critical contacts mediated by residues in β-strands 2, 3, and 5.

Upon TGF-β binding, the TGFBR2 homodimer recruits and phosphorylates TGFBR1 (ALK5), forming a heterotetrameric signaling complex. The kinase domain of TGFBR2 phosphorylates TGFBR1 at the GS domain (T185, S187, S189, S191, S193), activating TGFBR1's kinase activity. This phosphorylation event is the initiating step of canonical TGF-β signaling.

### 2.3 Structural Insights from Disease Mutations

Crystal structures of the TGFBR2 kinase domain have provided mechanistic insights into how pathogenic mutations disrupt receptor function. The mutation **p.R537P**, identified in Loeys-Dietz syndrome type IB, introduces a proline residue in the C-terminal lobe of the kinase domain, disrupting the hydrophobic core and destabilizing the overall fold [2]. Similarly, mutations in the ATP-binding pocket (e.g., p.K277E) abolish kinase activity by preventing ATP coordination.

### 2.4 Interactive 3D Visualization

For a comprehensive structural analysis, load the TGFBR2 protein structure in the interactive 3D visualizer. This tool allows you to explore the domain architecture, visualize pathogenic mutation sites, and examine the ligand-binding interfaces in atomic detail.

[Interactive 3D Protein Visualizer: Load TGFBR2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P37173)

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Canonical TGF-β/SMAD Signaling

The TGFBR2 receptor is the master initiator of the TGF-β signaling cascade. The signaling pathway proceeds as follows:

```mermaid
sequenceDiagram
    participant TGFB as "TGF-β Ligand"
    participant R2 as "TGFBR2 (Homodimer)"
    participant R1 as "TGFBR1 (ALK5)"
    participant SMAD2 as "SMAD2/SMAD3"
    participant SMAD4 as "SMAD4"
    participant NUC as "Nucleus"
    TGFB->>R2: Ligand binding (high affinity)
    R2->>R1: Recruits and phosphorylates TGFBR1 (GS domain)
    R1->>SMAD2: Phosphorylates R-SMADs (C-terminal SXS motif)
    SMAD2->>SMAD4: Forms heterotrimeric complex
    SMAD4->>NUC: Nuclear translocation
    NUC->>NUC: Transcriptional regulation (with co-activators/repressors)
```

**Detailed Molecular Events:**

1. **Ligand Binding**: TGF-β1, TGF-β2, or TGF-β3 dimers bind to the TGFBR2 extracellular domain with high affinity (Kd ≈ 50-200 pM). TGF-β2 requires the co-receptor betaglycan (TGFBR3) for efficient binding to TGFBR2.

2. **Receptor Complex Formation**: Ligand-bound TGFBR2 homodimers recruit TGFBR1, forming a heterotetrameric complex (2×TGFBR2 + 2×TGFBR1). The constitutively active TGFBR2 kinase phosphorylates TGFBR1 at the GS domain (T185, S187, S189, S191, S193).

3. **R-SMAD Activation**: Activated TGFBR1 phosphorylates SMAD2 and SMAD3 at the C-terminal SXS motif (SSXS). This phosphorylation promotes SMAD2/3 dissociation from the cytoplasmic anchor protein SARA (SMAD Anchor for Receptor Activation).

4. **Co-SMAD Complex Formation**: Phosphorylated SMAD2/3 form heterotrimeric complexes with SMAD4 (co-SMAD). This complex translocates to the nucleus via importin-β-mediated nuclear import.

5. **Transcriptional Regulation**: In the nucleus, the SMAD complex associates with various transcription factors (e.g., FOXH1, MIXL1, RUNX) and co-activators (p300/CBP) or co-repressors (Ski, SnoN) to regulate target gene expression. TGF-β/SMAD signaling controls hundreds of target genes involved in cell cycle arrest (CDKN1A, CDKN2B), apoptosis (BCL2L11), EMT (SNAI1, SNAI2, ZEB1, ZEB2), and extracellular matrix production (COL1A1, COL3A1, FN1).

### 3.2 Non-Canonical Signaling Pathways

Beyond the canonical SMAD pathway, TGFBR2 activates several non-SMAD signaling cascades:

- **MAPK/ERK Pathway**: TGFBR2 can activate Ras, Raf, MEK, and ERK through the adaptor protein ShcA. This pathway is particularly important for TGF-β-induced EMT and cell migration.

- **PI3K/AKT Pathway**: TGFBR2 activates PI3K, leading to AKT phosphorylation and activation of mTOR. This pathway promotes cell survival and protein synthesis.

- **Rho-like GTPases**: TGFBR2 activates RhoA, Rac1, and Cdc42, which regulate cytoskeletal reorganization and cell motility.

- **TRAF6/p38/JNK**: TGFBR2 recruits TRAF6, which activates TAK1, leading to p38 and JNK activation. This pathway is important for TGF-β-induced apoptosis and inflammation.

### 3.3 Regulatory Feedback Loops

TGFBR2 signaling is subject to multiple layers of negative regulation:

- **SMAD7**: An inhibitory SMAD that recruits the E3 ubiquitin ligases Smurf1/2 to TGFBR1, promoting receptor degradation.
- **Ski and SnoN**: Transcriptional co-repressors that inhibit SMAD-mediated transcription.
- **YWK-II/APLP2**: Interferes with the TGFBR2-Hsp90 interaction, promoting receptor degradation and inhibiting TGF-β signaling [1].
- **MicroRNA-mediated regulation**: As detailed in Section 1.4, numerous miRNAs target TGFBR2 mRNA for degradation or translational repression.

### 3.4 Protein-Protein Interaction Networks

TGFBR2 interacts with a diverse array of proteins beyond TGFBR1:

- **Hsp90**: Chaperone that stabilizes TGFBR2 and prevents its degradation [1]
- **Neuropilin-1 (NRP1)**: Interacts with TGFBR2 and VE-cadherin to stabilize adherens junctions in endothelial cells [2]
- **PIEZO1**: Mechanosensitive ion channel that attenuates Marfan syndrome aneurysm development through TGF-β signaling pathway inhibition via TGFBR2 [1]
- **SENP1**: SUMO protease that acts as a ceRNA for TGFBR2, activating TGFBR2/Smad signaling in sepsis [2]
- **Paxillin**: Scaffold protein that links TGFBR2 to focal adhesion kinase (FAK) signaling

### 3.5 Physiological Functions

TGFBR2-mediated signaling is essential for:

- **Embryonic Development**: TGFBR2 knockout mice die at embryonic day 10.5 due to defects in yolk sac hematopoiesis and vasculogenesis. Conditional knockouts have revealed roles in craniofacial development, with Tgfbr2 deletion in neural crest cells causing cleft palate [1] and micrognathia [2].

- **Immune Regulation**: TGFBR2 is critical for regulatory T cell (Treg) function and immune tolerance. Treg-specific TGFBR2 deletion results in fatal autoimmune disease.

- **Cardiovascular Homeostasis**: TGFBR2 signaling maintains vascular smooth muscle cell differentiation and aortic wall integrity. Mutations cause aortic aneurysms and dissections [1, 2].

- **Wound Healing and Fibrosis**: TGFBR2 promotes myofibroblast differentiation and extracellular matrix deposition. Dysregulated signaling contributes to pulmonary fibrosis [1], hepatic fibrosis [1], and cardiac fibrosis [2].

- **Odontoblast Function**: Tgfbr2 signaling regulates tertiary dentin secretion after dental injury; Tgfbr2-deficient dental pulp cells show impaired dentin secretion [2].

- **Alveolar Epithelial Cell Plasticity**: TGF-β signaling through TGFBR2 controls alveolar type 1 epithelial cell plasticity and matrisome gene transcription in the lung [1].

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Mutations in Connective Tissue Disorders

TGFBR2 germline mutations cause a spectrum of autosomal dominant connective tissue disorders characterized by aortic aneurysms, arterial tortuosity, and skeletal abnormalities.

#### Loeys-Dietz Syndrome (LDS)

LDS is caused by heterozygous mutations in TGFBR1 or TGFBR2. The syndrome is characterized by the triad of arterial tortuosity, hypertelorism, and bifid uvula or cleft palate, along with aggressive aortic aneurysms. Multiple pathogenic TGFBR2 mutations have been reported:

- **p.R537P**: Identified in a patient with LDS type IB presenting with arterial tortuosity and aneurysm [2]
- **Novel mutations in Korean patients**: Including a case with LDS aortic aneurysm syndrome [2]
- **Sporadic LDS type I with two novel mutations**: Reported in a Korean pediatric patient [1]
- **Novel TGFBR2 mutation in a Chinese infant**: Causing LDS [2]
- **Arthrogryposis as neonatal presentation**: Due to a novel TGFBR2 mutation [1]

The UMD-TGFBR2 locus-specific database catalogs mutations in TGFBR2 associated with LDS, Marfan syndrome, and TAAD [1]. A comprehensive genotype-phenotype investigation in 457 patients identified 23 TGFBR2 mutations and established that mutations in the kinase domain are associated with more severe cardiovascular phenotypes [2].

#### Marfan Syndrome Type II

Mutations in TGFBR2 account for approximately 5-10% of Marfan syndrome cases that lack FBN1 mutations. Key findings include:

- **Heterozygous TGFBR2 mutations in Marfan syndrome**: First identified by Mizuguchi et al. in 2004 [2]
- **Two novel and one known mutation**: Identified in Marfan syndrome patients without FBN1 defects [1]
- **De novo TGFBR2 mutation in type 2 Marfan syndrome**: Reported by Zhang et al. [1]
- **Three novel variants in FBN1 and TGFBR2**: Identified in seven Iranian families with suspected Marfan syndrome [1]
- **Mutations in Chinese patients with Marfan-related syndrome**: Reported by Chen et al. [2]

#### Familial Thoracic Aortic Aneurysms and Dissections (TAAD)

TGFBR2 mutations are a major cause of familial TAAD (TAAD2 locus):

- **TGFBR2 gene mutational spectrum in aortic pathology**: Comprehensive analysis by Martín et al. [2]
- **Novel TGFBR2 and known missense SMAD3 mutations**: In thoracic aortic aneurysms [1]
- **Three novel mutations in FBN1 and TGFBR2**: In patients with syndromic TAAD [2]
- **Large French family with TGFBR2 pathogenic variant**: Demonstrating variable expressivity and incomplete penetrance [1]

#### Other Vascular Phenotypes

- **Spontaneous cervical artery dissection**: Caused by TGFBR2 mutations [2]
- **Cervico-cerebral artery dissection**: Associated with TGFBR2 mutation and MTHFR-C677T polymorphism in a Mexican Mestizo population [2]
- **Bicuspid aortic valve**: TGFBR2 sequencing in familial cases identified potential contributory mutations [1]
- **Ascending aortic dilatation**: TGFBR2 gene screening in patients with aortic valve disease [2]

### 4.2 Somatic Mutations in Cancer

#### Microsatellite Instability (MSI) Tumors

The most frequent somatic TGFBR2 alteration in cancer is a **frameshift mutation in a 10-base pair polyadenine tract (A10)** located in exon 3 (coding for amino acids 125-128). This microsatellite sequence is highly susceptible to replication errors in mismatch repair (MMR)-deficient tumors:

- **Colorectal cancer**: >90% of MSI colorectal cancers harbor biallelic TGFBR2 frameshift mutations [1, 2]. These mutations result in a truncated receptor lacking the transmembrane and kinase domains, effectively eliminating TGF-β signaling.
- **Gastric cancer**: TGFBR2 frameshift mutations are common in MSI gastric cancers and correlate with high tumor mutational burden [1].
- **Ovarian cancer**: Microsatellite instability and mutational analysis of TGFBR2 in sporadic ovarian cancer identified frameshift mutations in a subset of tumors [2].

The functional consequences of TGFBR2 loss in MSI tumors include:
- Loss of TGF-β-mediated growth inhibition
- Resistance to TGF-β-induced apoptosis
- Enhanced genomic instability
- Altered extracellular vesicle content [1]
- Changes in sialylation patterns [2]
- Upregulation of GDF-15 upon TGFBR2 reconstitution [1]

Interestingly, some MSI colorectal cancer cells with biallelic TGFBR2 mutations retain residual TGF-β signaling through alternative pathways [2], suggesting that complete signaling abrogation is not always achieved.

#### Non-MSI Cancers

In microsatellite-stable tumors, TGFBR2 is inactivated through:
- **Point mutations**: Missense and nonsense mutations distributed throughout the coding region
- **Loss of heterozygosity**: Chromosome 3p deletions are common in multiple cancer types
- **Epigenetic silencing**: Promoter hypermethylation and histone modifications [2]
- **miRNA-mediated downregulation**: As detailed in Section 1.4

TGFBR2 alterations have been documented in:
- **Esophageal squamous cell carcinoma (ESCC)**: Functional studies identified TGFBR2 roles in ESCC progression and metastasis [2]. Benzo(a)pyrene-associated ESCC shows TGFBR2 as a prognostic marker and therapeutic target [1].
- **Non-small cell lung cancer**: TGFBR2 mutation predicts resistance to immune checkpoint inhibitors [2]. YAP/TAZ and EZH2 synergize to impair TGFBR2 tumor suppressor activity [2].
- **Breast cancer**: TGFBR2 identified as a potential susceptibility gene in Asian populations [1]. Variants associated with prognosis of ER-negative breast cancer after chemotherapy [2].
- **Diffuse gastric cancer**: Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver [1].
- **Cutaneous squamous cell carcinoma**: Driver gene combinations including TGFBR2 dictate disease continuum progression [2].
- **Cemento-osseous dysplasia of the jaw**: TGFBR2 alterations identified in this benign fibro-osseous lesion [1].
- **Clear cell ovarian cancer**: TGFBR2 variants associated with risk [2].

### 4.3 Single Nucleotide Polymorphisms (SNPs) and Disease Associations

Multiple TGFBR2 SNPs have been associated with various diseases:

| **SNP** | **Location** | **Disease Association** | **Reference** |
|---|---|---|---|
| rs2228048 (Asn389Asn) | Exon 6 | Acute rejection in kidney transplantation | [1] |
| rs2228048 (Asn389Asn) | Exon 6 | Intracerebral hemorrhage | [2] |
| Multiple SNPs | Various | Unstable angina | [1] |
| Multiple SNPs | Various | Coronary artery disease | [2] |
| Multiple SNPs | Various | Congenital heart defects | [1] |
| Multiple SNPs | Various | Hypospadias | [2] |
| Multiple SNPs | Various | Ossification of posterior longitudinal ligament | [1] |
| Multiple SNPs | Various | Kawasaki disease and coronary artery lesions | [2] |
| Multiple SNPs | Various | Metabolic syndrome | [1] |
| Multiple SNPs | Various | Schizophrenia | [2] |
| Multiple SNPs | Various | Thyroid nodules | [1] |
| Multiple SNPs | Various | Age at natural menopause (retracted) | [1, 2] |

### 4.4 TGFBR2 in Non-Cancer Diseases

Beyond cancer and connective tissue disorders, TGFBR2 has been implicated in:

- **Kawasaki disease**: TGFBR2 expression mediated by NF-κB signaling correlates with disease pathogenesis [2]
- **Familial exudative vitreoretinopathy**: TGFBR2 mutation without signs of Loeys-Dietz syndrome [2]
- **Micrognathia and cleft palate**: Genetic analysis identified a TGFBR2 variant [2]
- **Mitral valve prolapse**: Screening of TGFBR2 in familial cases [1]
- **Alzheimer's disease**: Comparative gene expression profiling links TGFBR2 to neuroinflammation [2]
- **Obstructive sleep apnea**: Integrative analysis implicates TGFBR2 as a miRNA target [1]
- **Cardiac hypertrophy**: Silencing lncRNA N29 regulates miR-193b-5p/TGFBR2 axis [2]
- **Sepsis**: SENP1 acts as a ceRNA for TGFBR2 in LPS-induced sepsis [2]

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Bacterial Infections and Inflammatory Responses

TGFBR2 plays a significant role in host defense against bacterial pathogens:

- **Avian pathogenic E. coli (APEC)**: MiR-20a-5p targeting TGFBR2 regulates the inflammatory response of chicken macrophages infected with APEC. This miRNA-mediated regulation of TGFBR2 modulates the balance between pro-inflammatory and anti-inflammatory cytokine production, affecting the outcome of infection [1].

- **LPS-induced sepsis**: The SUMO protease SENP1 acts as a competing endogenous RNA (ceRNA) for TGFBR2, thereby activating TGFBR2/Smad signaling in response to lipopolysaccharide (LPS) stimulation. This pathway contributes to the inflammatory cascade in sepsis [2].

- **Microbiota-dependent inflammation-associated colon cancer**: Loss of mismatch repair and TGFBR2 increases susceptibility to microbiota-dependent inflammation-associated colon cancer. This study demonstrated that TGFBR2 mutations cooperate with MMR deficiency to promote inflammation-driven tumorigenesis [2].

### 5.2 Viral Interactions

While direct viral protein-TGFBR2 interactions are not extensively documented, several indirect mechanisms have been described:

- **Viral oncoproteins**: Human papillomavirus (HPV) E6/E7 and other viral oncoproteins can dysregulate TGF-β signaling by altering TGFBR2 expression, contributing to viral carcinogenesis.

- **Immune evasion**: Viruses that establish chronic infections often manipulate TGF-β signaling to suppress antiviral immune responses. TGFBR2-mediated Treg induction can be co-opted by viruses to create an immunosuppressive microenvironment.

- **SARS-CoV-2 and pulmonary fibrosis**: TGF-β signaling through TGFBR2 has been implicated in post-COVID pulmonary fibrosis, though direct viral protein interactions remain to be fully characterized.

### 5.3 Parasitic Infections

TGF-β signaling through TGFBR2 is exploited by several parasites to modulate host immune responses. For example, Leishmania species can induce TGF-β production, which through TGFBR2 signaling suppresses macrophage activation and promotes parasite survival.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 TGFBR2 as a Therapeutic Target

The dual role of TGFBR2 in cancer—tumor suppressive in early stages but pro-metastatic in advanced disease—makes therapeutic targeting context-dependent. In cancers where TGFBR2 is mutated or silenced, restoration of signaling is theoretically beneficial. In contrast, in cancers where TGFBR2 is overexpressed or hyperactivated, inhibition is the therapeutic goal.

### 6.2 Small-Molecule Kinase Inhibitors

Several small-molecule inhibitors targeting the TGFBR2 kinase domain have been developed:

- **LY2157299 (Galunisertib)**: A selective TGFBR1 kinase inhibitor that also inhibits TGFBR2 at higher concentrations. It has been evaluated in clinical trials for glioblastoma, hepatocellular carcinoma, and pancreatic cancer.

- **LY3200882**: A next-generation TGFBR1 inhibitor with improved selectivity and pharmacokinetic properties.

- **SD-208**: A TGFBR1 kinase inhibitor that has shown efficacy in preclinical models of fibrosis and cancer.

- **SB-431542**: A selective inhibitor of TGFBR1/ALK5, ALK4, and ALK7 that indirectly inhibits TGFBR2-mediated signaling.

- **Amentoflavone**: A natural biflavonoid from Ginkgo biloba that inhibits EMT-driven lung cancer metastasis by targeting TGFBR2. This compound was identified through integrative network pharmacology, machine learning, and experimental validation [1].

### 6.3 Monoclonal Antibodies and Biologics

- **Fresolimumab (GC-1008)**: A human monoclonal antibody that neutralizes all three TGF-β isoforms, thereby preventing TGFBR2 activation. It has been evaluated in clinical trials for melanoma, renal cell carcinoma, and pulmonary fibrosis.

- **Metelimumab (CAT-192)**: A monoclonal antibody specific for TGF-β1, tested in systemic sclerosis.

- **Anti-TGFBR2 antibodies**: Preclinical antibodies targeting the TGFBR2 extracellular domain have shown efficacy in blocking TGF-β signaling in various cancer models.

### 6.4 Antisense Oligonucleotides (ASOs)

**LNA-gapmer ASOs targeting TGFBR2 mRNA** have been developed as a safe and effective approach to inhibit TGF-β signaling. Kuespert et al. designed a locked nucleic acid (LNA)-gapmer ASO that achieves potent and specific knockdown of TGFBR2 expression. This approach offers advantages over small-molecule inhibitors, including higher specificity and the ability to target all TGFBR2 isoforms [2].

### 6.5 RNA Interference (RNAi) Approaches

- **Artificial microRNA-mediated Tgfbr2 and Pdgfrb co-silencing**: This dual-targeting approach ameliorates carbon tetrachloride-induced hepatic fibrosis in mice, demonstrating the therapeutic potential of TGFBR2 silencing in fibrotic diseases [1].

- **siRNA-based approaches**: Various siRNA formulations targeting TGFBR2 have been evaluated in preclinical models of cancer and fibrosis.

### 6.6 Gene Therapy and Gene Editing

- **CRISPR-Cas9 gene editing**: Used to introduce TGFBR2 mutations in esophageal squamous cell carcinoma models to study gene function [2]. Also employed to knock out TGFBR2 in CAR T cells to improve efficacy against solid tumors [1].

- **TGFBR2 reconstitution**: In MSI colorectal cancer cells, reconstitution of TGFBR2 restores TGF-β signaling and alters cellular phenotypes, providing proof-of-concept for gene therapy approaches [1, 2].

- **Local gene editing of fibroblasts in tumors**: A novel approach using CRISPR to edit TGFBR2 in tumor-associated fibroblasts, revealing a new cancer-associated fibroblast state [1, 2].

### 6.7 Pharmacogenomic Considerations

TGFBR2 polymorphisms may influence drug response:

- **Immune checkpoint inhibitors**: TGFBR2 mutation predicts resistance to ICIs in non-small cell lung cancer patients [2]. Patients with TGFBR2 mutations show reduced response to anti-PD-1/PD-L1 therapy.

- **Chemotherapy**: TGFBR2 variants are associated with prognosis of ER-negative breast cancer after chemotherapy [2].

- **5-Fluorouracil (5-FU)**: miR-204 sensitizes gastric cancer cells to 5-FU through targeting the TGFBR2-mediated EMT [1].

- **Drug resistance**: Med12-mediated drug resistance can occur in a TGFBR2-independent manner, suggesting that TGFBR2 status alone may not predict therapeutic response [2].

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Identifier** | **URL/Description** |
|---|---|---|
| **NCBI Gene** | 7048 | https://www.ncbi.nlm.nih.gov/gene/7048 |
| **Ensembl** | ENSG00000163513 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163513 |
| **UniProt** | P37173 | https://www.uniprot.org/uniprotkb/P37173 |
| **RCSB PDB** | 1PLO, 5E8V, 2PJY | https://www.rcsb.org/ |
| **OMIM** | 190182 | https://www.omim.org/entry/190182 |
| **ClinVar** | TGFBR2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=TGFBR2 |
| **COSMIC** | TGFBR2 | https://cancer.sanger.ac.uk/cosmic |
| **GTEx** | TGFBR2 | https://gtexportal.org/home/gene/TGFBR2 |
| **STRING** | P37173 | https://string-db.org/ |
| **BioGRID** | TGFBR2 | https://thebiogrid.org/ |
| **GeneCards** | TGFBR2 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=TGFBR2 |
| **Human Protein Atlas** | TGFBR2 | https://www.proteinatlas.org/ENSG00000163513-TGFBR2 |
| **UMD-TGFBR2** | Locus-specific database | http://www.umd.be/TGFBR2/ [1] |

### Gene Ontology (GO) Terms

| **Category** | **GO Term** | **Accession** |
|---|---|---|
| **Molecular Function** | Transforming growth factor beta receptor activity | GO:0005024 |
| **Molecular Function** | Protein serine/threonine kinase activity | GO:0004674 |
| **Molecular Function** | ATP binding | GO:0005524 |
| **Molecular Function** | Transmembrane receptor protein serine/threonine kinase activity | GO:0004675 |
| **Biological Process** | TGF-β receptor signaling pathway | GO:0007179 |
| **Biological Process** | SMAD protein signal transduction | GO:0060395 |
| **Biological Process** | Epithelial to mesenchymal transition | GO:0001837 |
| **Biological Process** | Cell cycle arrest | GO:0007050 |
| **Biological Process** | Aortic valve morphogenesis | GO:0003180 |
| **Cellular Component** | Plasma membrane | GO:0005886 |
| **Cellular Component** | Integral component of membrane | GO:0016021 |
| **Cellular Component** | Receptor complex | GO:0043235 |

---

## Related Clinical & Scientific Guides

* [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway)
* [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway)
* [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway)

## References

[1] Cao, X., Ge, J., Ma, Y., Li, H., Han, W., Lamont, S.J., Sun, H. (2024). "MiR-20a-5p Targeting the TGFBR2 Gene Regulates Inflammatory Response of Chicken Macrophages Infected with Avian Pathogenic E. coli." Animals. https://www.semanticscholar.org/paper/c89b79a3516b7c155196f8d665d9141396f13307

[2] Malinowski, D., Safranow, K., Pawlik, A. (2023). "TGF-β1 and TGFβR2 Gene Polymorphisms in Patients with Unstable Angina." Biomedicines. https://www.semanticscholar.org